NASDAQ:MNOV - MediciNova Stock Price, Forecast & News

MediciNova trades on the NASDAQ under the ticker symbol "MNOV."

MediciNova, Inc. (NASDAQ:MNOV) announced its quarterly earnings results on Thursday, October, 29th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.04. View MediciNova's Earnings History.

MediciNova is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for MediciNova.

1 Wall Street analysts have issued 12-month target prices for MediciNova's shares. Their forecasts range from $22.00 to $22.00. On average, they expect MediciNova's share price to reach $22.00 in the next year. This suggests a possible upside of 340.9% from the stock's current price. View Analyst Price Targets for MediciNova.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MediciNova.

Media stories about MNOV stock have been trending very negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. MediciNova earned a coverage optimism score of -3.4 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for MediciNova.

MediciNova saw a decrease in short interest in January. As of January 15th, there was short interest totalling 2,940,000 shares, a decrease of 8.1% from the December 31st total of 3,200,000 shares. Based on an average daily trading volume, of 107,700 shares, the days-to-cover ratio is presently 27.3 days. Currently, 8.0% of the shares of the stock are sold short. View MediciNova's Current Options Chain.

Some companies that are related to MediciNova include Amphastar Pharmaceuticals (AMPH), ImmunoGen (IMGN), Rhythm Pharmaceuticals (RYTM), Dova Pharmaceuticals (DOVA), Collegium Pharmaceutical (COLL), Homology Medicines (FIXX), Endonovo Therapeutics (ENDV), CannTrust (CNTTF), Retrophin (RTRX), ANI Pharmaceuticals (ANIP), Provention Bio (PRVB), Arcus Biosciences (RCUS), DiaMedica Therapeutics (DMCAF), Frequency Therapeutics (FREQ) and Vanda Pharmaceuticals (VNDA).

Based on aggregate information from My MarketBeat watchlists, some companies that other MediciNova investors own include Novavax (NVAX), Progenics Pharmaceuticals (PGNX), Amicus Therapeutics (FOLD), Geron (GERN), NovaBay Pharmaceuticals (NBY), Cytokinetics (CYTK), Immunomedics (IMMU), Inovio Pharmaceuticals (INO), Opko Health (OPK) and Pieris Pharmaceuticals (PIRS).

MediciNova's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (1.73%), Geode Capital Management LLC (1.23%), Bank of New York Mellon Corp (0.36%), Charles Schwab Investment Management Inc. (0.23%), California Public Employees Retirement System (0.19%) and Goldman Sachs Group Inc. (0.13%). View Institutional Ownership Trends for MediciNova.

MNOV stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund. View Insider Buying and Selling for MediciNova.

MNOV stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, UBS Group AG, California Public Employees Retirement System, Barclays PLC, Marshall Wace LLP, Bank of America Corp DE, State Street Corp and Goldman Sachs Group Inc.. View Insider Buying and Selling for MediciNova.

Shares of MNOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MNOV stock can currently be purchased for approximately $4.99.

MediciNova has a market capitalization of $219.36 million. The biopharmaceutical company earns $-12,940,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. MediciNova employs 9 workers across the globe.View Additional Information About MediciNova.

The official website for MediciNova is http://medicinova.com/.

MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-373-1500 or via email at [email protected]